サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1319019

mRNA治療薬市場：タイプ、用途、最終用途別-2023～2030年の世界予測

mRNA Therapeutics Market by Type, Application, End Use - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 196 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
mRNA治療薬市場：タイプ、用途、最終用途別-2023～2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

mRNA治療薬の世界市場は、2023年に338億2,000万米ドル、CAGR24.58%で大きく成長し、2030年には1,582億米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のmRNA治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.mRNA治療薬の世界市場規模および予測は？

2.予測期間中、世界のmRNA治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.mRNA治療薬の世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.mRNA治療薬の世界市場における競争戦略は？

5.mRNA治療薬の世界市場における技術動向と規制の枠組みは？

6.mRNA治療薬の世界市場における主要ベンダーの市場シェアは？

7.mRNA治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 慢性疾患や感染症の発生率の増加
      • がんのワクチンと治療に対する需要の高まり
      • mRNA治療薬の需要の急増と、大規模なシーケンスプロジェクトに対する政府の取り組みの急増
    • 抑制要因
      • 高額な研究コストとmRNA定量化失敗の脅威
    • 機会
      • 重要なバイオテクノロジー関連の研究開発への取り組みと医療技術の進歩
      • 強力な新製品パイプラインを備えたがんの個別化治療法の開発
    • 課題
      • mRNA治療薬に関する規制上の懸念と戦略
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 mRNA治療薬市場：タイプ別

  • イントロダクション
  • 予防ワクチン
  • 治療薬
  • 治療用ワクチン

第7章 mRNA治療薬市場：用途別

  • イントロダクション
  • 感染症
  • 腫瘍
  • 希少遺伝病
  • 呼吸器疾患

第8章 mRNA治療薬市場：最終用途別

  • イントロダクション
  • 病院とクリニック
  • 研究機関

第9章 南北アメリカのmRNA治療薬市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のmRNA治療薬市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのmRNA治療薬市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. MRNA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MRNA THERAPEUTICS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. MRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 5. MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 6. MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2022 VS 2030 (%)
  • FIGURE 7. MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. MRNA THERAPEUTICS MARKET DYNAMICS
  • FIGURE 9. MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. MRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. MRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 9. MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. MRNA THERAPEUTICS MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. MRNA THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 14. MRNA THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. MRNA THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 143. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 144. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 145. MRNA THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-205091A88BDC

The Global mRNA Therapeutics Market is forecasted to grow significantly, with a projected USD 33.82 billion in 2023 at a CAGR of 24.58% and expected to reach a staggering USD 158.20 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global mRNA Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global mRNA Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Prophylactic Vaccines, Therapeutic Drugs, and Therapeutic Vaccines. The Therapeutic Vaccines is projected to witness significant market share during forecast period.

Based on Application, market is studied across Infectious Diseases, Oncology, Rare Genetic Diseases, and Respiratory Diseases. The Rare Genetic Diseases is projected to witness significant market share during forecast period.

Based on End Use, market is studied across Hospitals & Clinics and Research Organizations. The Hospitals & Clinics is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global mRNA Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global mRNA Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global mRNA Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global mRNA Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global mRNA Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global mRNA Therapeutics Market?

6. What is the market share of the leading vendors in the Global mRNA Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global mRNA Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. mRNA Therapeutics Market, by Type, 2022 vs 2030
  • 4.3. mRNA Therapeutics Market, by Application, 2022 vs 2030
  • 4.4. mRNA Therapeutics Market, by End Use, 2022 vs 2030
  • 4.5. mRNA Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of chronic and infectious diseases
      • 5.1.1.2. Growing demand for cancer vaccines and treatments
      • 5.1.1.3. Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of research and threat of failure in quantification of mRNA
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
      • 5.1.3.2. Development of personalized therapeutics for cancer with strong pipeline of new products
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory concerns and strategies for mRNA therapeutics
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. mRNA Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Prophylactic Vaccines
  • 6.3. Therapeutic Drugs
  • 6.4. Therapeutic Vaccines

7. mRNA Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Infectious Diseases
  • 7.3. Oncology
  • 7.4. Rare Genetic Diseases
  • 7.5. Respiratory Diseases

8. mRNA Therapeutics Market, by End Use

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Research Organizations

9. Americas mRNA Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific mRNA Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa mRNA Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing